{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:08:05Z","timestamp":1773972485829,"version":"3.50.1"},"reference-count":8,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Perampanel (<jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content>) has been approved for adjunctive treatment of partial\u2010onset seizures in patients age 12\u00a0years and older. In Germany, PER was licensed and marketed in September of 2012. At our tertiary referral epilepsy center, a couple of difficult\u2010to\u2010treat patients were awaiting this introduction of <jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content>; therefore, we were able to initiate treatment in many patients within a short period of time. For this report we collected and analyzed the data of the first patients who had been started on add\u2010on <jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content> between September and December of 2012, so that we were able to evaluate at least 6\u00a0months of treatment when we made this analysis. At cutoff in June of 2013, 74 patients could be analyzed. Mean age was 38.4\u00a0years (range 15\u201371\u00a0years). <jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content> doses ranged from 4 to 14\u00a0mg (mean 8.8\u00a0mg). All patients took <jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content> once daily at bedtime. Seventy\u2010one patients had focal epileptic seizures; the remaining four patients had Lennox\u2010Gastaut syndrome. Considering the last 3\u00a0months of observation compared with baseline, 34 patients (46%) were responders with a reduction of seizure frequency of at least 50%. Ten patients of these (14% of all) were seizure\u2010free. Adverse events were reported in 40 patients (54%). Leading side effects were somnolence (n\u00a0=\u00a031, 42%) and dizziness (n\u00a0=\u00a013, 18%), followed by ataxia, irritability, falls, cognitive slowing, and depression in single cases. Six\u2010month retention rate was 70%. Our first clinical experiences with add\u2010on <jats:styled-content style=\"fixed-case\">PER<\/jats:styled-content> in a highly selected group of difficult\u2010to\u2010treat epilepsies are promising.<\/jats:p>","DOI":"10.1111\/epi.12492","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T19:58:02Z","timestamp":1389211082000},"page":"16-18","source":"Crossref","is-referenced-by-count":54,"title":["First clinical experiences with perampanel\u2014The Kork experience in 74 patients"],"prefix":"10.1111","volume":"55","author":[{"given":"Bernhard J.","family":"Steinhoff","sequence":"first","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Bacher","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bast","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"Kornmeier","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kurth","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Scholly","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke M.","family":"Staack","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Kork Epilepsy Center Kehl\u2010Kork Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12212"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03648.x"},{"key":"e_1_2_6_8_1","first-page":"375","article-title":"The new antiepileptic drug perampanel","volume":"30","author":"Steinhoff BJ","year":"2012","journal-title":"Arzneimitteltherapie"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12100"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.12492","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.12492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:38:49Z","timestamp":1694651929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.12492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":8,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/epi.12492"],"URL":"https:\/\/doi.org\/10.1111\/epi.12492","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}